Results 21 to 30 of about 8,705 (221)

Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2).

PLoS ONE, 2021
SARS-CoV-2 variants are emerging with potential increased transmissibility highlighting the great unmet medical need for new therapies. Niclosamide is a potent anti-SARS-CoV-2 agent that has advanced in clinical development.
Anne Weiss, Franck Touret, Cecile Baronti, Magali Gilles, Bruno Hoen, Antoine Nougairède, Xavier de Lamballerie, Morten O A Sommer   +7 more
doaj   +1 more source

Involvement of Up-Regulation of DR5 Expression and Down-Regulation of c-FLIP in Niclosamide-Mediated TRAIL Sensitization in Human Renal Carcinoma Caki Cells

Molecules, 2018
Niclosamide is used to treat intestinal parasite infections, as being an anthelmintic drug. Recently, several papers suggest the niclosamide inhibits multiple signaling pathways, which are highly activated and mutated in cancer.
Jeong Mi Yun, Seon Min Woo, Seung Un Seo, Kyoung-Jin Min, Dong Eun Kim, Taeg Kyu Kwon   +5 more
doaj   +1 more source

Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. [PDF]

, 2016
Considerable evidence from both clinical and experimental studies suggests that androgen receptor variants, particularly androgen receptor variant 7 (AR-V7), are critical in the induction of resistance to enzalutamide and abiraterone.
Armstrong, Cameron, Gao, Allen C, Liu, Chengfei, Lou, Wei, Zhu, Yezi   +4 more
core   +1 more source

LGR5 is associated with tumor aggressiveness in papillary thyroid cancer. [PDF]

, 2015
PurposeLeucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) is a cancer stem cell marker and a down-stream target in Wnt/β-catenin signaling. In human papillary thyroid cancer (PTC), over activation of Wnt/β-catenin has been associated with
Diehl, Anna Mae, Henderson, Brittany Bohinc, Jiang, Xiaoyin, Michelotti, Gregory, Sosa, Julie Ann   +4 more
core   +3 more sources

Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer

Scientific Reports, 2021
Niclosamide has preclinical activity against a wide range of cancers. In prostate cancer, it inhibits androgen receptor variant 7 and synergizes with abiraterone. The approved niclosamide formulation has poor oral bioavailability.
Mamta Parikh, Chengfei Liu, Chun-Yi Wu, Christopher P. Evans, Marc Dall’Era, Daniel Robles, Primo N. Lara, Neeraj Agarwal, Allen C. Gao, Chong-Xian Pan   +9 more
doaj   +1 more source

Study and implementation of urogenital schistosomiasis elimination in Zanzibar (Unguja and Pemba islands) using an integrated multidisciplinary approach [PDF]

, 2012
: BACKGROUND: Schistosomiasis is a parasitic infection that continues to be a major public health problem in many developing countries being responsible for an estimated burden of at least 1.4 million disability-adjusted life years (DALYs) in Africa ...
Albonico, M., Ali, S. M., Ame, S. M., Colley, D. G., Fenwick, A., Gouvras, A., Khamis, I. S., Knopp, S., Mohammed, K. A., Person, B., Rollinson, D., Savioli, L., Utzinger, J.   +12 more
core   +1 more source

New life for an old drug: In vitro and in vivo effects of the anthelmintic drug niclosamide against Toxoplasma gondii RH strain

International Journal for Parasitology: Drugs and Drug Resistance, 2019
Toxoplasma gondii is the causative agent of toxoplasmosis and causes serious public health problems. However, the current treatment drugs have many limitations, such as serious side effects.
Ji Li Zhang, Hong Fei Si, Xiao Fei Shang, Xu Kun Zhang, Bing Li, Xu Zheng Zhou, Ji Yu Zhang   +6 more
doaj   +1 more source

Are we ready for Taenia solium cysticercosis elimination in sub-Saharan Africa? [PDF]

, 2016
The World Health Organization announced in November 2014 at the fourth international meeting on 'the control of neglected zoonotic diseases - from advocacy to action', that intervention tools for eliminating Taenia solium taeniosis/cysticercosis (TSTC ...
Braae, Uffe Christian, Gabriël, Sarah, Johansen, Maria Vang, Magnussen, Pascal, Trevisan, Chiara   +4 more
core   +3 more sources

Niclosamide as a Repurposing Drug against Corynebacterium striatum Multidrug-Resistant Infections

Antibiotics, 2022
Corynebacterium striatum (C. striatum) is an emerging multidrug-resistant (MDR) pathogen associated with nosocomial infections. In this scenario, we screened the antimicrobial activity of the anthelmintic drugs doramectin, moxidectin, selamectin and ...
Veronica Folliero, Federica Dell’Annunziata, Emanuela Roscetto, Marcella Cammarota, Anna De Filippis, Chiara Schiraldi, Maria Rosaria Catania, Vincenzo Casolaro, Alessandro Perrella, Massimiliano Galdiero, Gianluigi Franci   +10 more
doaj   +1 more source

WNT signalling in prostate cancer [PDF]

, 2017
Genome sequencing and gene expression analyses of prostate tumours have highlighted the potential importance of genetic and epigenetic changes observed in WNT signalling pathway components in prostate tumours-particularly in the development of castration-
A Ghoshal, A Gurney, A Jimeno, A Klaus, A Mallinger, A Mikels, A Säfholm, A Säfholm, AB El-Khoueiry, AC Vidal, AD,MR Kohn, AH Nile, AL Giraudet, AS Khaja, AS Perry, ASS Khaja, B Bilir, B Chen, B Madan, B Madan, BJ Feldman, BT MacDonald, C Fukukawa, C Lin, C Liu, C Liu, C Logan, C Niehrs, CL Chen, CM Cruciat, CS Grasso, CY Janda, D Grandy, D Robinson, D Zheng, DS Yee, DT Miyamoto, E Lee, E Lee, E Sandsmark, EE Storm, F Janku, F Ma, FC Gonsalves, G Chen, G O'Hurley, G Schulte, G Wang, GT Lee, H Beltran, H Clevers, H Hanaki, H Kimura, H Kumon, H Kumon, H Peradziryi, H Yamamoto, H Zhu, H-X Hao, HW Park, HX Hao, I Bisson, J Chinison, J Green, J Hao, J Liu, J Veeck, J Weischenfeldt, J-H Geng, JC Brase, JC Francis, JN Anastas, JP Dijksterhuis, JR Packer, K Ahmed, K Shojima, KC Valkenburg, KD Proffitt, KE Livermore, KH Emami, L Azzolin, L Fang, L Wu, L Zheng, LE Pascal, M Bordonaro, M Cojoc, M de la Roche, M Kahn, M Mancini, M Mazon, M Volante, M Yang, MD Shultz, MT Veeman, N Borcherding, N Li, N Takebe, NK Thudi, NN Yokoyama, O Dakhova, P Bovolenta, P García-Tobilla, P Le, P Polakis, P Rajan, P Uysal-Onganer, P Uysal-Onganer, PA Watson, R Eferl, R Kolb, R Siegel, R van Amerongen, R van Amerongen, RE O'Cearbhaill, RM Kypta, Robert Kypta, S Gupta, S Josson, S Martinez, S Perner, S Piccolo, S Takahashi, S Terry, S Thiele, S Thiele, S Zhang, S-P Huang, SA Tomlins, SH Lee, SJ Cooper, SJ Hotte, SJ Jung, SP Acebron, SP Acebron, T Chandrasekar, T Haikarainen, T Karantanos, T Malinauskas, T Phesse, TD Rachner, TM Bauman, TS Gujral, V Teneggi, Virginia Murillo-Garzón, W Lu, W Lu, W Tian, W Wang, X Chen, X Jiang, X Li, X Varelas, Y Eun-Jin, Y Kawano, Y Komiya, Y Li, Y Sun, Y Sun, Y Xie, Y Yang, Y Zhou, Y Zong, Z Debebe, Z Steinhart, ZG Li, ZJ Debruine   +166 more
core   +2 more sources